May 28, 2015 / 6:27 PM / 2 years ago

U.S. court grants exclusivity for Amarin's Vascepa

May 28 (Reuters) - A U.S. district court has ruled that Amarin Corp’s fish oil pill, Vascepa, is eligible for five years of marketing exclusivity, setting aside a U.S. Food and Drug administration decision.

Amarin’s shares rose as much as 44 percent to $2.80 on the Nasdaq. The stock was trading up 19 percent at $2.33 on Thursday afternoon.

Vascepa was approved in 2012 to reduce high levels of blood fat called triglycerides in patients not using cholesterol-lowering statins.

The case is Amarin v. U.S. FDA and HHS, U.S. District Court for the District of Columbia, No. 14-cv-00324. (1.usa.gov/1QdfHeC) (Reporting by Natalie Grover and Ankur Banerjee in Bengaluru; Editing by Don Sebastian)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below